Cargando…
Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy
[Image: see text] Cancer immunotherapy is a powerful treatment strategy that mobilizes the immune system to fight disease. Cancer vaccination is one form of cancer immunotherapy, where spatiotemporal control of the delivery of tumor-specific antigens, adjuvants, and/or cytokines has been key to succ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228553/ https://www.ncbi.nlm.nih.gov/pubmed/35756370 http://dx.doi.org/10.1021/acscentsci.2c00227 |
_version_ | 1784734508681003008 |
---|---|
author | Huang, Ziyin Callmann, Cassandra E. Wang, Shuya Vasher, Matthew K. Evangelopoulos, Michael Petrosko, Sarah Hurst Mirkin, Chad A. |
author_facet | Huang, Ziyin Callmann, Cassandra E. Wang, Shuya Vasher, Matthew K. Evangelopoulos, Michael Petrosko, Sarah Hurst Mirkin, Chad A. |
author_sort | Huang, Ziyin |
collection | PubMed |
description | [Image: see text] Cancer immunotherapy is a powerful treatment strategy that mobilizes the immune system to fight disease. Cancer vaccination is one form of cancer immunotherapy, where spatiotemporal control of the delivery of tumor-specific antigens, adjuvants, and/or cytokines has been key to successfully activating the immune system. Nanoscale materials that take advantage of chemistry to control the nanoscale structural arrangement, composition, and release of immunostimulatory components have shown significant promise in this regard. In this Outlook, we examine how the nanoscale structure, chemistry, and composition of immunostimulatory compounds can be modulated to maximize immune response and mitigate off-target effects, focusing on spherical nucleic acids as a model system. Furthermore, we emphasize how chemistry and materials science are driving the rational design and development of next-generation cancer vaccines. Finally, we identify gaps in the field that should be addressed moving forward and outline future directions to galvanize researchers from multiple disciplines to help realize the full potential of this form of cancer immunotherapy through chemistry and rational vaccinology. |
format | Online Article Text |
id | pubmed-9228553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-92285532022-06-25 Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy Huang, Ziyin Callmann, Cassandra E. Wang, Shuya Vasher, Matthew K. Evangelopoulos, Michael Petrosko, Sarah Hurst Mirkin, Chad A. ACS Cent Sci [Image: see text] Cancer immunotherapy is a powerful treatment strategy that mobilizes the immune system to fight disease. Cancer vaccination is one form of cancer immunotherapy, where spatiotemporal control of the delivery of tumor-specific antigens, adjuvants, and/or cytokines has been key to successfully activating the immune system. Nanoscale materials that take advantage of chemistry to control the nanoscale structural arrangement, composition, and release of immunostimulatory components have shown significant promise in this regard. In this Outlook, we examine how the nanoscale structure, chemistry, and composition of immunostimulatory compounds can be modulated to maximize immune response and mitigate off-target effects, focusing on spherical nucleic acids as a model system. Furthermore, we emphasize how chemistry and materials science are driving the rational design and development of next-generation cancer vaccines. Finally, we identify gaps in the field that should be addressed moving forward and outline future directions to galvanize researchers from multiple disciplines to help realize the full potential of this form of cancer immunotherapy through chemistry and rational vaccinology. American Chemical Society 2022-05-20 2022-06-22 /pmc/articles/PMC9228553/ /pubmed/35756370 http://dx.doi.org/10.1021/acscentsci.2c00227 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Huang, Ziyin Callmann, Cassandra E. Wang, Shuya Vasher, Matthew K. Evangelopoulos, Michael Petrosko, Sarah Hurst Mirkin, Chad A. Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy |
title | Rational Vaccinology: Harnessing Nanoscale Chemical
Design for Cancer Immunotherapy |
title_full | Rational Vaccinology: Harnessing Nanoscale Chemical
Design for Cancer Immunotherapy |
title_fullStr | Rational Vaccinology: Harnessing Nanoscale Chemical
Design for Cancer Immunotherapy |
title_full_unstemmed | Rational Vaccinology: Harnessing Nanoscale Chemical
Design for Cancer Immunotherapy |
title_short | Rational Vaccinology: Harnessing Nanoscale Chemical
Design for Cancer Immunotherapy |
title_sort | rational vaccinology: harnessing nanoscale chemical
design for cancer immunotherapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228553/ https://www.ncbi.nlm.nih.gov/pubmed/35756370 http://dx.doi.org/10.1021/acscentsci.2c00227 |
work_keys_str_mv | AT huangziyin rationalvaccinologyharnessingnanoscalechemicaldesignforcancerimmunotherapy AT callmanncassandrae rationalvaccinologyharnessingnanoscalechemicaldesignforcancerimmunotherapy AT wangshuya rationalvaccinologyharnessingnanoscalechemicaldesignforcancerimmunotherapy AT vashermatthewk rationalvaccinologyharnessingnanoscalechemicaldesignforcancerimmunotherapy AT evangelopoulosmichael rationalvaccinologyharnessingnanoscalechemicaldesignforcancerimmunotherapy AT petroskosarahhurst rationalvaccinologyharnessingnanoscalechemicaldesignforcancerimmunotherapy AT mirkinchada rationalvaccinologyharnessingnanoscalechemicaldesignforcancerimmunotherapy |